May 17, 2020

Amgen Purchases New Cancer Drug Through Onyx Pharmaceuticals

3 min
Amgen Purchases New Cancer Drug Through Onyx Pharmaceuticals .jpg
Written by Alyssa Clark In an extremely expensive transaction this past weekend, Amgen agreed to buy Onyx Pharmaceuticals for an astounding $10.4 bill...

Written by Alyssa Clark


In an extremely expensive transaction this past weekend, Amgen agreed to buy Onyx Pharmaceuticals for an astounding $10.4 billion due to their groundbreaking discoveries in three anticancer treatments.

Breaking into the anticancer drug realm, Amgen (being one of the world’s largest biotechnology companies) has finally caught the fever in developing anticancer treatments and decided to get “in on the action” by acquiring Onyx’s latest research and products. The contract states that Amgen will offer $125 a share in cash with a tender offer for Onyx’s shares, and will close at the end of the fourth quarter.

This deal is the second largest in Amgen’s history behind the 2002 Immunex deal that occurred in 2002.

Constantly trying to keep product lines fresh and up-to-date with the most modern industry-affiliated drugs, the pharmaceutical industry has seen some infamous takeovers throughout its days as they try to remain on top of an ever-changing industry like the pharmaceutical one. Aside from the industry-known Sanofi-Aventis and Gilead Sciences takeovers in the past years, this take-over of Amgen’s will now rank within the Top 5 biggest takeovers of any pharmaceutical company, especially in biotechnology, according to the numbers recorded from the Standard & Poor’s Capital IQ.

The spike and consistent value of biotechnology stock has given biotech companies little or no desire to part with their stock, thus generating a gap within the market. With this constant desire for more and more takeovers throughout the industry, this deal was surprisingly slow in its cultivation and execution over the years.

“Amgen has a unique opportunity to add value to Kyprolis, a product which is at an early and promising stage of its launch,” Robert A. Bradway, chief executive of Amgen, based in Thousand Oaks, Calif., said in a statement Sunday.

The newly acquired Amgen drug, within its first 6 months of sales, had recorded sales of $125 million in just that short time-span alone. After winning approval from the necessary inter-industry officials, analysts project that the drug will continue to grow and sustain to an incredible $2 billion over the next several years if the drug begins being used earlier on in the treatment process.

These specific anticancer drugs named Kyprolis were designed to target multiple myeloma, a bone marrow cancer, and were approved in the United States last July. Another drug that Amgen already sells for cancer treatment is entitled Vectibix which treats colorectal cancer, but sales haven’t been up to the company’s expectation.

Industry competition is sure to be increased by the acquisition with the industry already being led by Celegene, and their blockbuster drug Revlimid. Another drug, by the same company, named Pomalyst will compete directly with Kyprolis thus generating even more competition within this already innately competitive industry. Another potential negative would be the cost: if Kyprolis is approved, it is likely that the drug will have to be used simultaneously with another anticancer drug like Celegene which will up patient and company costs.

However, Amgen maintains more than enough financial means to support its recent decision and the company stands firmly behind the recent takeover. Amgen is more than excited about the upcoming potential gain from this purchase, and is fully prepared with $8.1 billion in bank loans and $22 billion in cash for any bumps along their way to future successes. 


About the Author

Alyssa Clark is the Editor of Healthcare Global

Share article

May 12, 2021

OMNI: First-ever platform to launch citizen RPA developers

3 min
OMNI is empowering employees to become ‘citizen RPA developers’, democratising automation and other AI technologies

Robotic process automation (RPA) is the fastest growing segment of the enterprise software market due to its many benefits - from reducing manual errors to processing tasks faster. For businesses to truly benefit from this technology, RPA needs democratisation, and this is where citizen RPA development comes in. 

Gartner describes a citizen RPA developer as "a user who creates new business applications for consumption by others using development and runtime environments sanctioned by corporate IT.” This could be anyone using IT tools and technology, not limited to IT specialists. 

The work citizen RPA developers do spans from identifying automation opportunities to developing RPA architecture and solution proposals, focusing on scalability and extensibility. By deploying citizen RPA developers, organisations can enable enterprise automation and digital transformation on a much larger scale. 

This is particularly beneficial for businesses struggling to undertake digital transformation, as a citizen RPA development programme can help drive adoption of automation as a strategic growth driver at multiple levels. With increased adoption, the cost of digital transformation becomes lower, increasing RoI. 

Technology needs to be democratised – right from low-code and no-code platforms, business process modelling and identifying automation opportunities to decision-makers at all levels, creating a pool of early adopters. This group could comprise people across different functions, especially those who are aware of customer preferences, industry trends and end user experience.

But how can organisations harness the power of citizen RPA development? Step forward AiRo Digital Labs, a Chicago-headquartered global tech company. 

AiRo provides innovative digital and automation solutions for the healthcare, pharmaceutical and life sciences sectors. In 2021 they launched OMNI, a subscription-based, SaaS platform to help clients accelerate their citizen RPA developer program and build digital centres of excellence (COE) within their organisation. 

OMNI provides a personal RPA coach and virtual digital playground that helps enterprises rapidly build and scale automation, removing the risk of failure or talent gaps. The latter is key as research has shown that digitalisation is far more successful when championed by internal employees. 

This has the added bonus of empowering employees - who will self-learn technologies including robotic process automation (RPA), artificial intelligence, machine learning, chatbots, and natural language processing (NLP), reducing the lead time for new applications and technology, as well as reducing technical gaps, making up for skills shortages and enabling their business to respond faster to critical market challenges. The virtual sandbox within OMNI gives access to all the major intelligent automation platforms where citizen RPA developers can build DIY digital prototypes. Additionally, they can access more than 150 digital assets within OMNI marketplace. 

The platinum helpdesk of OMNI acts as your personal coach and is available 24 x 7 to address issues during the digital learning, prototype building, and digital governance journey.  

Another key benefit is that it enables digitalisation to be bespoke to each organisation, compared to off-the-shelves initiatives plugged into the enterprise. Individual organisation's objectives decide the scope and size of the process. 

As Gartner state, in today’s world of SaaS, cloud, low-code and “no-code” tools, everyone can be a developer. 

Share article